Seres Therapeutics (MCRB) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Seres Therapeutics (MCRB) over the last 5 years, with Sep 2025 value amounting to $0.94.
- Seres Therapeutics' EPS (Weighted Average and Diluted) fell 91.92% to $0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.29, marking a year-over-year increase of 964.71%. This contributed to the annual value of -$0.81 for FY2024, which is 45.64% up from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' EPS (Weighted Average and Diluted) is $0.94, which was up 141.41% from -$2.27 recorded in Q2 2025.
- Seres Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $13.87 during Q4 2024, with a 5-year trough of -$5.49 in Q1 2024.
- Its 3-year average for EPS (Weighted Average and Diluted) is $1.57, with a median of -$0.27 in 2023.
- Examining YoY changes over the last 5 years, Seres Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 5,237.04% in 2024 and a maximum decrease of 1,305.56% in 2024.
- Over the past 5 years, Seres Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.55 in 2021, then grew by 1.82% to -$0.54 in 2022, then soared by 50.00% to -$0.27 in 2023, then soared by 5,237.04% to $13.87 in 2024, then crashed by 91.92% to $0.94 in 2025.
- Its EPS (Weighted Average and Diluted) was $0.94 in Q3 2025, compared to -$2.27 in Q2 2025 and $3.75 in Q1 2025.